COMBIVIR DIN 02239213
Health Canada record
| Active ingredient(s) | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AR01 ZIDOVUDINE AND LAMIVUDINE |
| Original market date | 08-Dec-1998 |
| Current status date | 31-Dec-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
ViiV Healthcare ULC — licence 101800, currently licensed, last inspection rating C (2025-09-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LAMIVUDINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02192691 | 3TC | VIIV HEALTHCARE ULC | Solution | LAMIVUDINE 10 MG | Marketed |
| 02192683 | 3TC | VIIV HEALTHCARE ULC | Tablet | LAMIVUDINE 150 MG | Marketed |
| 02247825 | 3TC | VIIV HEALTHCARE ULC | Tablet | LAMIVUDINE 300 MG | Marketed |
| 02369052 | APO-LAMIVUDINE | APOTEX INC | Tablet | LAMIVUDINE 150 MG | Marketed |
| 02369060 | APO-LAMIVUDINE | APOTEX INC | Tablet | LAMIVUDINE 300 MG | Marketed |
| 02393239 | APO-LAMIVUDINE HBV | APOTEX INC | Tablet | LAMIVUDINE 100 MG | Marketed |
| 02375540 | APO-LAMIVUDINE-ZIDOVUDINE | APOTEX INC | Tablet | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Marketed |
| 02281368 | APO-ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE | APOTEX INC | Tablet | LAMIVUDINE 150 MG; NEVIRAPINE 200 MG; ZIDOVUDINE 300 MG | Approved |
| 02414414 | AURO-LAMIVUDINE/ZIDOVUDINE | AURO PHARMA INC | Tablet | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Marketed |
| 02507129 | JAMP LAMIVUDINE | JAMP PHARMA CORPORATION | Tablet | LAMIVUDINE 300 MG | Marketed |
| 02507110 | JAMP LAMIVUDINE | JAMP PHARMA CORPORATION | Tablet | LAMIVUDINE 150 MG | Marketed |
| 02502801 | JAMP LAMIVUDINE / ZIDOVUDINE | JAMP PHARMA CORPORATION | Tablet | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Marketed |
| 02512467 | JAMP LAMIVUDINE HBV | JAMP PHARMA CORPORATION | Tablet | LAMIVUDINE 100 MG | Marketed |
| 02282216 | LAMIVUDINE ORAL SOLUTION | AUROBINDO PHARMA LIMITED (UNIT III) | Solution | LAMIVUDINE 10 MG | Approved |
| 02410575 | AURO-LAMIVUDINE | AURO PHARMA INC | Tablet | LAMIVUDINE 150 MG | Cancelled Post Market |
| 02410567 | AURO-LAMIVUDINE | AURO PHARMA INC | Tablet | LAMIVUDINE 300 MG | Cancelled Post Market |
| 02239193 | HEPTOVIR | GLAXOSMITHKLINE INC | Tablet | LAMIVUDINE 100 MG | Cancelled Post Market |
| 02239194 | HEPTOVIR | GLAXOSMITHKLINE INC | Solution | LAMIVUDINE 5 MG | Cancelled Post Market |
| 02387247 | TEVA-LAMIVUDINE/ZIDOVUDINE | TEVA CANADA LIMITED | Tablet | LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14471 | 2013-06-17 | New Drug Submission (NDS) | Administrative transfer of Drug Identification Numbers |
| 11666 | 2010-08-18 | New Drug Submission (NDS) | Manufacturer name change |
| 10882 | 2009-12-21 | New Drug Submission (NDS) | Manufacturer name change |
| 9972 | 2008-12-24 | New Drug Submission (NDS) | Manufacturer name change |
| 2360 | 2001-12-21 | New Drug Submission (NDS) | CHANGE IN MANUFACTURER NAME |
| 3014 | 1998-12-03 | New Drug Submission (NDS) |
International API supply for LAMIVUDINE
8 valid EDQM Certificates of Suitability from 8 holders. 24 active FDA Drug Master Files.
Request a quote for COMBIVIR